Pulse lineResearch With Heart Logo

Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study.

TitleCytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study.
Publication TypeJournal Article
Year of Publication1994
AuthorsSorlie PD, Adam E, Melnick SL, Folsom A, Skelton T, Chambless LE, Barnes R, Melnick JL
JournalJ Med Virol
Volume42
Issue1
Pagination33-7
Date Published1994 Jan
ISSN0146-6615
KeywordsAntibodies, Viral, Arteriosclerosis, Carotid Artery Diseases, Case-Control Studies, Cytomegalovirus, Cytomegalovirus Infections, Herpes Simplex, Herpesvirus 1, Human, Herpesvirus 2, Human, Humans, Prospective Studies, Risk Factors, United States
Abstract

Ubiquitous viruses such as members of the human herpes virus group, particularly cytomegalovirus (CMV), have been proposed to be clinically important agents in the initiation and progression of atherosclerosis. Antibodies to CMV and herpes simplex virus type 1 (HSV1) and type 2 (HSV2) were determined in 340 matched case-control pairs from the Atherosclerosis Risk in Communities (ARIC) Study. Cases were defined by B-mode ultrasonography as persons with thickened carotid artery walls consistent with early atherosclerosis but without a history of cardiovascular disease. Controls were defined as persons without thickened walls or history of cardiovascular disease. The case-control odds ratio for CMV antibodies was 1.55 (P = .03), for HSV 1.41 (P = .07), and for HSV2 0.91 (P = .63). When adjustment was made for potential confounders, the odds ratios were 1.36 for CMV (P = .24), 1.21 for HSV1 (P = .45), and 0.61 (P = .05) for HSV2. These results suggest a modest association between CMV and asymptomatic carotid wall thickening consistent with early atherosclerosis.

DOI10.1002/jmv.1890420107
Alternate JournalJ Med Virol
PubMed ID8308517
Grant ListN01-HC-55015 / HC / NHLBI NIH HHS / United States
N01-HC-55016 / HC / NHLBI NIH HHS / United States
N01-HC-55018 / HC / NHLBI NIH HHS / United States